[F-18-FDG positron emission tomography in the diagnosis of ovarian recurrence. Comparison with CT scan and CA 125]
- PMID: 12846945
- DOI: 10.1016/s0212-6982(03)72189-2
[F-18-FDG positron emission tomography in the diagnosis of ovarian recurrence. Comparison with CT scan and CA 125]
Abstract
Objective: The aim of this study was to evaluate the clinical utility of FDG-PET for detecting recurrent disease in patients with ovarian cancer.
Material and methods: Twenty-one FDG-PET studies performed in 19 patients who had previously undergone surgery and chemotherapy for ovarian cancer were reviewed retrospectively. In a maximum interval of one week regarding the FDG-PET study, computed tomography (CT) was performed and CA-125 levels were measured. In 16 cases the relapse suspicion was due to elevation of the tumor marker CA125 and in 5 cases it was due to CT. PET images were obtained at 45 min after the intravenous injection of 370 MBq of FDG. The results of the visual interpretation were compared with the CA125 levels and the images of the CT, and related to the definitive diagnosis. Recurrence was confirmed in 19/21 cases, by means of pathological findings (11 cases) and clinical follow-up for a median of 11 months in the others.
Results: Recurrence was confirmed in 16 cases with increased CA-125 and the tumor marker was true-negative in 2 disease free cases, but there were 3 false-negative results (sensitivity of 84 % and accuracy of 86 %). CT correctly identified 9 cases with recurrence, but it was false-negative in 10 cases and false-positive in 2 disease free patients (sensitivity of 47 % and accuracy of 43 %). FDG-PET correctly detected the 19 cases with recurrence but it was false-positive in 2 cases with a sensitivity of 100 % and accuracy of 90 %. In 3 patients with CA125 false-negative and 10 patients with false-negative CT, FDG-PET was positive and recurrence was confirmed.
Conclusion: These preliminary results suggest that in the follow-up of patients with ovarian cancer FDG-PET could detect recurrence with higher accuracy than CT, and even with higher sensitivity than the tumor marker CA125, being useful at the same time to locate the recurrence when the tumor marker is positive.
Similar articles
-
The value of 18F-FDG PET/CT imaging combined with detection of CA125 and HE4 in the diagnosis of recurrence and metastasis of ovarian cancer.Eur Rev Med Pharmacol Sci. 2020 Jul;24(13):7276-7283. doi: 10.26355/eurrev_202007_21882. Eur Rev Med Pharmacol Sci. 2020. PMID: 32706065
-
Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose.Eur J Nucl Med Mol Imaging. 2002 Jun;29(6):797-803. doi: 10.1007/s00259-001-0750-9. Epub 2002 Mar 19. Eur J Nucl Med Mol Imaging. 2002. PMID: 12029554 Clinical Trial.
-
Usefulness of CA125 and its kinetic parameters and positron emission tomography/computed tomography (PET/CT) with fluorodeoxyglucose ([18F] FDG) in the detection of recurrent ovarian cancer.Med Clin (Barc). 2018 Aug 10;151(3):97-102. doi: 10.1016/j.medcli.2017.11.019. Epub 2017 Dec 21. Med Clin (Barc). 2018. PMID: 29276012 English, Spanish.
-
[Positron emission tomography (PET) in malignant ovarian tumors].Ginekol Pol. 2013 Aug;84(8):720-5. doi: 10.17772/gp/1630. Ginekol Pol. 2013. PMID: 24191507 Review. Polish.
-
Surveillance procedures for patients treated for epithelial ovarian cancer: a review of the literature.Int J Gynecol Cancer. 2007 Jan-Feb;17(1):21-31. doi: 10.1111/j.1525-1438.2007.00826.x. Int J Gynecol Cancer. 2007. PMID: 17291227 Review.
Cited by
-
Evaluation of follow-up strategies for women with epithelial ovarian cancer following completion of primary treatment.Cochrane Database Syst Rev. 2023 Aug 31;8(8):CD006119. doi: 10.1002/14651858.CD006119.pub4. Cochrane Database Syst Rev. 2023. PMID: 37650760 Free PMC article.
-
Evaluation of follow-up strategies for patients with epithelial ovarian cancer following completion of primary treatment.Cochrane Database Syst Rev. 2014 Sep 8;2014(9):CD006119. doi: 10.1002/14651858.CD006119.pub3. Cochrane Database Syst Rev. 2014. Update in: Cochrane Database Syst Rev. 2023 Aug 31;8:CD006119. doi: 10.1002/14651858.CD006119.pub4. PMID: 25198378 Free PMC article. Updated.
-
Diagnostic Value of PET/CT for Ovarian Cancer Recurrence or Metastasis in Postoperative Patients With Elevated Serum CA125 Levels: A Systematic Review and Meta-Analysis.Cancer Innov. 2025 Jun 2;4(4):e70015. doi: 10.1002/cai2.70015. eCollection 2025 Aug. Cancer Innov. 2025. PMID: 40463490 Free PMC article.
-
Diagnostic accuracy of FDG PET in the follow-up of platinum-sensitive epithelial ovarian carcinoma.Eur J Nucl Med Mol Imaging. 2007 Sep;34(9):1396-405. doi: 10.1007/s00259-007-0366-9. Epub 2007 Feb 21. Eur J Nucl Med Mol Imaging. 2007. PMID: 17318549
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous